Results 21 to 30 of about 2,077 (188)
Clinical and morphological aspects of vulvovaginal atrophy
Vulvovaginal atrophy is one of the most annoying and undesirable manifestations of estrogen deficiency. 77% of women feel uncomfortable to discuss the symptoms with their doctor.
I. A. Apolikhina, E. A. Gorbunova
doaj +3 more sources
Vulvovaginal atrophy in postmenopausal women: diagnosis and modern-day treatments
The article is devoted to the study of modern methods of diagnosis and treatment of benign diseases of the vulva and vagina in postmenopausal women.
K. R. Bahtiyarov +2 more
doaj +2 more sources
The effectiveness of rehabilitation in vulvovaginal atrophy
Objective: to evaluate the effectiveness and safety of rehabilitation programmes in patients with vulvovaginal atrophy (VVA).Material and methods. The study involved 350 patients with VVA in surgical (n=140) and natural (n=140) menopause, the control ...
D. М. Ampilogova +5 more
doaj +3 more sources
Vulvovaginal atrophy (VVA) is a common and underreported condition associated with decreased estrogenization of the vaginal tissue. Symptoms include dryness, irritation, soreness, and dyspareunia with urinary frequency, urgency, and urge incontinence. It can occur at any time in a woman's life cycle, although more commonly in the postmenopausal phase ...
Deborah J Rhodes, Lynne T Shuster
exaly +5 more sources
Fractional CO2 Laser for Treatment of Vulvovaginal Atrophy: A Short Time Follow-up [PDF]
Objective: The aim of this study was to evaluate the safety and efficacy of fractional CO2 laser for treatment of vulvovaginal atrophy. Materials and methods: In this clinical trial study, we evaluated the laser effect on vulvovaginal atrophy in 47 women
Zinat Ghanbari +6 more
doaj +2 more sources
Vulvovaginal atrophy: modern approaches to diagnostics and management
The aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.
V. H. Siusiuka +4 more
doaj +3 more sources
Treatment of postmenopausal vulvovaginal atrophy with estriol: a scientific update for 2014–2018
Due to the increase in life expectancy, today, most women live in a state of estrogen deficiency for more than a third of their life time. According to the recent document on the stages of aging of the female reproductive system (the STRAW+10 working ...
A. D. Makatsariya +3 more
doaj +2 more sources
Diagnostics and management of vulvovaginal atrophy according to the international guidelines
Vulvovaginal atrophy is one of the genitourinary symptoms caused by estrogen deficiency which leads to the development of immature vaginal epithelium, glycogen deficiency, reduction or even elimination of lactobacilli, and secondary genitourinary tract ...
K. V. Dmitrienko +2 more
doaj +2 more sources
Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause. [PDF]
The effects of oral vitamin D supplements on vaginal health in postmenopausal women with vulvovaginal atrophy (VVA) was evaluated. A double-blinded, randomized placebo-controlled trial was conducted for 12 weeks to investigate changes on vaginal maturation index (VMI), vaginal pH, and the visual analog scale (VAS) of VVA symptoms.
Kamronrithisorn T +4 more
europepmc +4 more sources
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy. [PDF]
Ospemifene-a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013-is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia.
Shin JJ, Kim SK, Lee JR, Suh CS.
europepmc +4 more sources

